Most practitioners treating depression are still asking one question: which neurotransmitter is deficient? Research in neuroimmunology has been asking a different one for years: which inflammatory pathway is active? The clinical gap between those two questions is where Dr. Datis Kharrazian and the Kharrazian Institute focus a significant portion of their practitioner training — specifically, how to assess neuroinflammation as a driver of mood disorders and cognitive dysfunction.
This is not a fringe hypothesis. The evidence base connecting systemic inflammation, glial cell activation, and depression has grown substantially over the past two decades. The clinical challenge is that most practitioners were never trained to evaluate it.
How Peripheral Inflammation Becomes a Brain Problem
Systemic inflammation does not stay neatly contained in the periphery. Circulating inflammatory cytokines — including TNF-alpha, IL-1β, and IL-6 — can cross or signal across the blood-brain barrier, activating resident immune cells in the brain called microglia and astroglia. Once activated, these glial cells release their own inflammatory mediators, shifting the brain's functional environment in ways that affect neurotransmission, neuroplasticity, and mood regulation.
Research in neuropsychiatry demonstrates that this pathway is clinically relevant in a substantial subset of patients with depression. It is not that neurotransmitters are irrelevant — it is that the inflammatory cascade upstream often drives the neurotransmitter dysregulation downstream. Dr. Kharrazian's clinical teaching addresses this distinction directly, training practitioners to evaluate the source rather than only the symptom.
One mechanism worth understanding is glial cell priming. Patients with a history of chronic infection, significant psychological trauma, or longstanding autoimmune activity may develop a state in which their microglia are chronically sensitized. Primed microglia respond to minor inflammatory stimuli with a disproportionate activation response. The clinical presentation can look like treatment-resistant depression, extreme emotional reactivity, or rapid cognitive deterioration following an illness or stressor that a patient without primed glial cells would handle without incident.
Neuroinflammatory Symptoms That Distinguish This Presentation
The symptom picture of neuroinflammation-driven mood disorders differs meaningfully from classic melancholic depression or anxiety. Practitioners trained in neuroinflammation clinical assessment learn to recognize a specific cluster.
Brain fog is the most common complaint — not sadness, not hopelessness, but a pervasive cognitive cloudiness that patients describe as thinking through static. Alongside that: poor brain endurance (the patient functions adequately in the morning but is cognitively depleted by early afternoon), slowed cognitive processing speed, and mood instability that fluctuates with inflammatory load rather than life circumstance. These patients often report that their mood worsened after a viral illness, a gut flare, or a period of significant physical stress. That history is a clinical signal.
Psychological stress adds another layer. Research in psychoneuroimmunology demonstrates that psychological stress alone can increase microglial activation and elevate peripheral cytokine levels. The stress-inflammation-mood loop is bidirectional: inflammation drives mood instability, and mood instability amplifies inflammatory tone. For patients who present with depression that is treatment-resistant or that clearly tracks with inflammatory events, this bidirectional relationship is the clinical target.
Neuroinflammation Clinical Assessment: Building the Evaluation
Evaluating neuroinflammation in a mood disorder patient requires integrating clinical history, symptom patterns, and targeted biomarkers. Dr. Kharrazian's coursework teaches practitioners to structure this evaluation systematically rather than rely on a single lab value or screening tool.
Clinical history: The intake should include documented history of head trauma, chronic infections (including Lyme, EBV, herpes simplex), gut permeability issues (celiac disease, inflammatory bowel conditions), and any diagnosed or suspected autoimmune conditions. Each of these can prime glial cells or chronically elevate inflammatory cytokine load. A patient with Hashimoto's thyroiditis who also presents with depression is not experiencing two separate problems — the neuroimmune connection between peripheral autoimmunity and brain inflammation is well-documented in research and is a core focus of Dr. Kharrazian's training curriculum.
Cognitive screening: The Montreal Cognitive Assessment (MoCA) provides a practical, in-office neuroinflammation clinical assessment tool. It evaluates multiple cognitive domains — visuospatial function, executive function, attention, memory, and language — in approximately 10 minutes. Used serially across appointments, it documents progression or improvement in response to clinical intervention. Patients with active neuroinflammation frequently show processing speed deficits and working memory difficulties on the MoCA before those deficits are apparent in a standard clinical interview.
Biomarkers: S100-B is a protein released by astroglia when blood-brain barrier integrity is compromised. Elevated serum S100-B indicates that the barrier has been breached, allowing peripheral inflammatory signals direct CNS access. This is not a standard panel in most clinical settings, but it is clinically meaningful when neuroinflammation is suspected. High-sensitivity CRP, inflammatory cytokine panels, and markers of intestinal permeability round out the systemic picture. Research in functional neurology demonstrates that high cytokine load in treatment-resistant depression is one of the strongest predictors of poor antidepressant response — which is why this workup is not academic; it changes the clinical strategy.
Dietary and lifestyle assessment: Blood sugar dysregulation is a direct driver of neuroinflammatory tone. Chronic hyperglycemia and insulin resistance increase glial cell activation, reduce neuroplasticity, and impair the blood-brain barrier. Sleep deprivation elevates inflammatory cytokines within 24 hours of a disrupted night. Sedentary lifestyle reduces BDNF and blunts the brain's anti-inflammatory mechanisms. These are not soft lifestyle factors to mention at the end of an appointment — they are mechanistic drivers that belong in the primary assessment.
Why Standard Depression Treatment Falls Short in These Patients
Conventional antidepressants were developed to modulate neurotransmitter availability. For patients whose depression is downstream of active neuroinflammation, correcting serotonin reuptake without addressing the inflammatory source produces partial or temporary response at best. Research in psychopharmacology has begun to explain why: certain antidepressants, including SSRIs and ketamine, produce anti-inflammatory effects in addition to their neurotransmitter effects. Their efficacy in some patient populations may be attributable more to those anti-inflammatory mechanisms than to serotonin modulation specifically.
This does not mean antidepressants are the wrong tool. It means that in neuroinflammation-driven depression, anti-inflammatory intervention — whether pharmacological, nutritional, or lifestyle-based — is a required component of the protocol, not an optional adjunct.
Dr. Kharrazian's clinical training teaches practitioners to identify which patients fall into this category based on their presentation, history, and biomarker profile, then to build protocols that address blood-brain barrier integrity, reduce glial cell activation, stabilize blood sugar, and support neuroplasticity alongside any existing pharmacological care.
Implementing This Approach in Practice
The practitioner who can identify neuroinflammation as a driver of depression is not replacing the psychiatrist or the therapist. They are adding a clinical layer that the current mental health system largely does not evaluate. Patients who have cycled through multiple antidepressants without sustained response, who describe their depression in terms of cognitive dysfunction rather than primarily emotional pain, and whose mood clearly tracks with inflammatory events are the patients who benefit most from this evaluation.
The MoCA can be added to any intake. Inflammatory biomarkers can be ordered alongside a standard metabolic panel. The clinical history questions that reveal glial priming risk take under five minutes to add to a new patient form. None of this requires a specialized facility. It requires a trained clinical thought process that starts with the question: is there active neuroinflammation here, and if so, what is driving it?
Key Takeaways
- Peripheral inflammatory cytokines can activate CNS microglia and astroglia, producing depression and cognitive dysfunction through neuroimmune mechanisms distinct from classical neurotransmitter deficiency.
- Glial cell priming — a sensitized microglial state resulting from prior trauma, chronic infection, or autoimmune activity — creates disproportionate neuroinflammatory responses to minor inflammatory triggers.
- The Montreal Cognitive Assessment provides a practical in-office tool for documenting cognitive changes associated with neuroinflammation, particularly processing speed and working memory deficits.
- S100-B serum levels serve as a clinically accessible biomarker for blood-brain barrier breakdown, indicating direct peripheral-to-CNS inflammatory access.
- Treatment-resistant depression with cognitive features warrants a full neuroinflammatory workup. Addressing the inflammatory source is a required component of the clinical protocol, not an optional add-on.
Frequently Asked Questions
Neuroinflammation clinical assessment evaluates whether systemic or CNS-based inflammation is contributing to a patient's mood disorder. It includes clinical history, cognitive screening tools like the MoCA, and biomarkers such as S100-B and inflammatory cytokines to identify glial cell activation as an underlying driver of depression.
Activated microglia and astroglia release inflammatory mediators that disrupt neurotransmission, reduce neuroplasticity, and impair brain endurance. Research in neuroimmunology demonstrates this pathway is mechanistically distinct from — and often upstream of — the neurotransmitter dysregulation conventionally targeted in depression treatment.
Glial priming is a chronic sensitization state in which microglia respond to minor inflammatory stimuli with exaggerated activation. It develops from prior trauma, chronic infection, or autoimmune conditions. Clinically, primed patients present with treatment-resistant depression and mood instability that disproportionately tracks with inflammatory events.
S100-B indicates blood-brain barrier breakdown. High-sensitivity CRP, IL-6, TNF-alpha, and other inflammatory cytokines reflect peripheral inflammatory load. In treatment-resistant depression, elevated cytokine levels are associated with poor antidepressant response, making this panel clinically actionable rather than academic.
Yes. Blood sugar dysregulation, chronic sleep disruption, and sedentary behavior all elevate inflammatory cytokine levels through documented mechanisms. In patients with underlying glial priming, these lifestyle-driven inflammatory insults can be sufficient to trigger or sustain active neuroinflammatory depression.
About the Author
Dr. Datis Kharrazian, PhD, DHSc, DC, MS, MMSc, FACN is a Harvard Medical School research fellow and researcher at Massachusetts General Hospital's Department of Neurology, specializing in autoimmunity and neuroimmunology. He serves as Associate Clinical Professor at Loma Linda University School of Medicine and is the author of Why Do I Still Have Thyroid Symptoms When My Lab Tests Are Normal and Why Isn't My Brain Working. He holds fellowships with the American College of Nutrition and the Royal Society of Medicine (UK), a Diplomate of the Board of Nutrition Specialists, and membership in the American Association of Immunologists. The Kharrazian Institute serves more than 5,000 physicians and healthcare providers worldwide.
Practitioner Training in Neuroinflammation and Functional Neurology
The Kharrazian Institute offers advanced clinical training in neuroinflammation assessment and brain-based functional medicine. Practitioners learn to apply these evaluation strategies and build personalized protocols for complex patients with treatment-resistant mood disorders and cognitive dysfunction.
